创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction to the features of the in vivo tumor experiment platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-12 14:01
  • Views:

(Summary description)In the vast field of biomedical research, tumor research has always been the focus of much attention. With the advancement of science and technology, tumor experimental platforms are also constantly developing and improving. Among them, InnoModels' in vivo tumor experimental platform has become an important choice for researchers because of its uniqueness and excellent value

InnoModels: Introduction to the features of the in vivo tumor experiment platform

(Summary description)In the vast field of biomedical research, tumor research has always been the focus of much attention. With the advancement of science and technology, tumor experimental platforms are also constantly developing and improving. Among them, InnoModels' in vivo tumor experimental platform has become an important choice for researchers because of its uniqueness and excellent value

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-12 14:01
  • Views:
Information

In the vast field of biomedical research, tumor research has always been the focus of much attention. With the advancement of science and technology, tumor experimental platforms are also constantly developing and improving. Among them, InnoModels' in vivo tumor experimental platform has become an important choice for researchers because of its uniqueness and excellent value.
Huge tumor cell line library
The InnoModels in vivo tumor platform has a large tumor cell line library, covering more than 400 different tumor cell lines, covering a wide range of cancer types and subtypes. This diverse collection provides researchers with an abundance of choices, allowing them to select the cell line that best suits their research and ensures relevance to their specific area of study. Whether it is lung cancer, breast cancer, liver cancer, or any other type of cancer, InnoModels Biotechnology has the appropriate tumor cell line to meet the needs of researchers.
More than ten years of experience in experimental design and management
In addition to the huge tumor cell line library, the in vivo tumor experimental platform of InnoModels Biotechnology also has a professional team with rich experience. This team consists of researchers, QC experts and project managers who have more than a decade of experience in the field of CDX modeling. Their shared knowledge and expertise ensures the smooth execution of experiments and provides high-quality experimental data.

 


In addition, InnoModels' intracorporeal tumor experimental platform focuses on the traceability of experimental records. They maintain thorough and traceable records of experiments, ensuring that researchers can easily meet reporting and documentation standards. This not only helps to protect the safety of the research, but also provides researchers with reliable data support to make their research results more convincing and credible.
Excellent Laboratory Conditions and Technical Support
InnoModels' intracorporeal tumor platform also has excellent experimental conditions and technical support. They have advanced experimental equipment and high level experimental technology, which can provide researchers with high quality experimental environment and conditions. At the same time, they also provide comprehensive technical support and solutions to help researchers solve all kinds of problems and difficulties encountered in the experimental process.
Personalized service to meet different needs
InnoModels' intracorporeal tumor experimental platform also focuses on providing personalized services to meet the needs of different researchers. They can provide customized experimental plans and personalized service support according to the specific needs and research directions of researchers. This service model enables researchers to focus more on the research itself, improving research efficiency and quality of results.
Extensive Collaboration and Communication
InnoModels Biotechnology Intracorporeal Tumor Experiment Platform also actively participates in a wide range of collaborations and exchanges. They have established good relationships with domestic and international research institutes, universities and hospitals to jointly promote the development of tumor research. By organizing regular academic conferences, seminars and research project collaborations, InnoModels maintains close contact and communication with professionals from all walks of life to share the latest research results and technological advances.
In conclusion, with its unique features such as a huge tumor cell line library, rich experience in experimental design and management, excellent experimental conditions and technical support, as well as personalized service and extensive cooperation and communication, InnoModels' in vivo tumor experimental platform has become an important force in the field of tumor research. It provides a reliable experimental platform and support for a wide range of researchers, and makes important contributions to the development of tumor research. In the future, InnoModels' in vivo tumor experimental platform will continue to devote itself to innovation and development, bringing more breakthroughs and progress to the field of tumor research.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司